Black patients responded least to escalated lupus treatment in a UK register

Ethnic disparities in lupus outcomes are among the best-documented inequalities in rheumatology: Black and South Asian patients tend to present with more severe systemic lupus erythematosus (SLE) and to fare worse over time. What has been missing is evidence on whether patients from different ethnic groups actually respond differently once treatment is escalated. A longitudinal cohort study published on 3 November in The Lancet Rheumatology set out to measure exactly that [s1].

What the study did

The researchers drew on the British Isles Lupus Assessment Group Biologics Register (BILAG-BR), a UK cohort recruiting from 64 secondary and tertiary rheumatology and nephrology centres [s1]. Eligible patients were aged 16 or older with active moderate-to-severe SLE — defined by at least one BILAG A score, at least two BILAG B scores, or a SLEDAI-2K score of at least 6 — who had recently started rituximab or belimumab, or standard immunosuppressive therapy [s1]. Ethnicity was grouped as White, South Asian, Black, East Asian, or mixed or other. The primary outcome was major clinical response (MCR) at 6 and 12 months, modelled with mixed-effects logistic regression [s1].

This is an observational register, not a randomised trial. It can show who responds, not prove why — and ethnicity here stands in for a tangle of biological, social, and access-related factors the register cannot fully separate.

The numbers

Between 1 July 2010 and 10 November 2021, 1688 patients were recruited; after eligibility screening, 422 were included [s1]. Of those, 383 (91%) were female and the median age was 40.5 years (IQR 31.3–50.8). The cohort was 245 (58%) White, 77 (18%) South Asian, 70 (17%) Black, 19 (5%) East Asian, and 11 (3%) mixed or other [s1]. At baseline, Black patients had higher disease activity, greater organ damage, and more comorbidities [s1].

At 12 months, 99 of 422 patients (23%) had met MCR criteria [s1]. Broken down by group, response was reached by eight of 19 East Asian patients (42%), 23 of 77 South Asian (30%), 60 of 245 White (24%), seven of 70 Black (10%), and one of 11 mixed or other (9%) [s1]. In the adjusted five-group model, patients of Black ethnicity had markedly lower odds of response than White patients: an odds ratio of 0.13 (95% CI 0.02–0.88) [s1].

The group sizes are the first thing to register. East Asian patients, who posted the highest response rate at 42%, numbered only 19, and the mixed or other category just 11 — small enough that a handful of patients shifts the percentage sharply [s1]. The two groups the study can speak about with most confidence are the White majority and the Black and South Asian cohorts, which between them account for the large bulk of the 422. Against that White reference of 24%, the Black group's 10% is the gap the adjusted model then tries to quantify [s1].

How to read the headline figure

That 0.13 odds ratio is striking, but the confidence interval — 0.02 to 0.88 — is wide, which is what happens when only seven of 70 Black patients responded. The direction is clear and statistically significant; the precise magnitude is not. The interval's upper bound still sits below 1, so a real reduction in odds is the study's finding, but treat "roughly an eighth the odds" as the centre of a broad range, not a fixed number.

The most important context is the first number, not the last. Fewer than a quarter of all patients met major response after their treatment was escalated [s1]. The disparity sits on top of a therapy that, in this real-world register, was falling short for the large majority regardless of ethnicity.

Why baseline burden matters

Black patients entered with worse disease — more activity, more damage, more comorbidity [s1]. Some of the response gap may reflect that starting point rather than a different biological response to the drugs, and the adjusted model is an attempt, not a guarantee, to separate the two. European guidelines already frame SLE care around treat-to-target control of disease activity and minimising glucocorticoid exposure [s2]; this study suggests that where patients begin on that path, and who reaches the target, are not evenly distributed.

What to watch

The authors read their results as support for more personalised, equitable approaches to SLE management rather than as a verdict on any single drug [s1]. The open questions are whether the same pattern appears in other registries and health systems, how much is explained by baseline severity versus access and adherence, and what earlier or more intensive strategies might do for the groups responding least. A register can flag the inequality precisely; closing it will take work this study does not attempt.

This article is informational and does not constitute medical advice.